NCT02231489View on ClinicalTrials.gov

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-42756493 Tablet

Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.

DRUG

JNJ-42756493 Capsule

Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.

DRUG

JNJ-61818549

Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02231489 - Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants | Biotech Hunter | Biotech Hunter